common.study.topics.clinical

PENTHROXâ„¢ in the Canadian Emergency Department (ED)

common.study.values.description

PENTHROXâ„¢ in the Canadian Emergency Department (ED)

This Canadian, multi-centre, prospective, real world study is designed to evaluate the effectiveness of low dose methoxyflurane (MEOF) (PENTHROXa"c) for the treatment of moderate to severe pain associated with trauma in the Canadian ED.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Methoxyflurane 3mL

As soon as possible following enrollment and initial procedures, the patient will be supplied with a PENTHROXâ„¢ kit which includes one inhaler containing 3 mL of MEOF for pain management. A member of the research team will train the patient to self-administer MEOF. PENTHROXâ„¢ is an approved (trademarked) product in Canada and is commercially available in a combination blister pack with one 3 mL sealed bottle and one PENTHROXâ„¢ inhaler with the Activated Carbon (AC) chamber.

participant.views.study.view.additional

participant.views.study.view.scientific-title

A Phase IV Real World Study on the Use of Low Dose Methoxyflurane (PENTHROXâ„¢) for the Treatment of Moderate to Severe Trauma Pain in the Canadian Emergency Department

common.study.values.clinical-trial-id

NCT03868436

participant.views.study.view.id

bo2mka